

# CITATION REPORT

List of articles citing

## The Importance of Countering Biosimilar Disparagement and Misinformation

DOI: 10.1007/s40259-020-00433-y  
BioDrugs, 2020, 34, 407-414.

**Source:** <https://exaly.com/paper-pdf/75579105/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption. <i>BioDrugs</i> , <b>2020</b> , 34, 783-796	7.9	15
27	Biyobenzer <i>Bar. Beykent Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi</i> ,		
26	Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	9
25	Process development of recombinant <i>Aspergillus flavus</i> urate oxidase production in <i>Pichia pastoris</i> intracellularly and its characterization as a potential biosimilar. <i>Process Biochemistry</i> , <b>2021</b> , 102, 376-385	4.8	0
24	Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	2
23	Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey. <i>BioDrugs</i> , <b>2021</b> , 35, 363-372	7.9	3
22	General characteristics of clinical trials for biosimilar drugs. <i>Marmara Medical Journal</i> ,		
21	Biosimilar Uptake: The Importance of Healthcare Provider Education. <i>Pharmaceutical Medicine</i> , <b>2021</b> , 35, 215-224	2.3	1
20	Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. <i>Drugs</i> , <b>2021</b> , 81, 1881-1896	12.1	6
19	What influences healthcare providers' prescribing decisions? Results from a national survey. <i>Research in Social and Administrative Pharmacy</i> , <b>2021</b> , 17, 1770-1779	2.9	2
18	Interchangeability of Biosimilars: Overcoming the Final Hurdles. <i>Drugs</i> , <b>2021</b> , 81, 1897-1903	12.1	1
17	Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 789640	5.6	0
16	The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems.. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 52, 151939	5.3	1
15	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 820755	4.9	1
14	Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars.. <i>Research in Social and Administrative Pharmacy</i> , <b>2022</b> ,	2.9	0
13	Exploring the Reasons Behind the Substantial Discontinuation Rate Among Patients Taking CT-P13 in a Large Tertiary Hospital in Western Switzerland: A Retrospective Cohort Study Using Routinely Collected Medical Data.. <i>Drugs - Real World Outcomes</i> , <b>2022</b> ,	2.2	0
12	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. <i>BioDrugs</i> ,	7.9	0

11	Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One. <i>BioDrugs</i> ,	7.9	
10	Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies. <i>BioDrugs</i> ,	7.9	2
9	Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars. <b>2022</b> , 14, 1766		2
8	Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. 135245852211162		
7	Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines.		
6	Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa. Volume 16, 161-171		○
5	Current Expertise, Opinions, and Attitude toward TNF-? Antagonist Biosimilars among Physicians: A Self-Administered Online Survey in Western Switzerland. <b>2022</b> , 10, 2152		○
4	Pharmacists confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study. <b>2022</b> , 100199		○
3	An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain. 9,		1
2	Consistency of Product Quality for SB5, an Adalimumab Biosimilar.		○
1	ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology.		○